Core Viewpoint - Huadong Medicine (000963) is actively communicating with its partner regarding the supply timeline for the product "Yanduo" [1] Group 1: Product Details - MediBeacon TGFR consists of a transcutaneous glomerular filtration rate measurement device and Lumitrace (Remabizine) injection, managed as a medical device and a drug in China respectively [1] - The transcutaneous glomerular filtration rate measurement device was approved in February 2025, and the company has completed inventory preparations with its partner in advance [1] - The drug portion will be produced independently by the company, ensuring a stable supply with sufficient buffer periods and multiple safeguard mechanisms [1]